Shar Ireland bid $30.6 billion for baxalta

Source: e-medicine Facebook 2015-8-5 after June, shire PLC, an Irish manufacturer of rare disease drugs, reported that it expected to swallow "Europe's Gilead" acteron at a price of $18.9 billion, and tried again to build the strongest product line in the field of rare diseases On August 4, shire officially announced that it has issued an active acquisition offer to baxalta Inc., a US biopharmaceutical company, and plans to purchase baxalta Inc through a share exchange transaction for about US $30.6 billion Under the terms of the offer, each of baxalta's shareholders will receive 0.1687 shares of shire American Depository stock (ads), equivalent to $45.23 per share at Monday's closing price, 36% higher than the Monday's closing price of baxalta's shares Driven by the news, baxalta's shares surged 27% to $42.10 before trading It is reported that in July, shire privately negotiated for baxalta for $30 billion, but it was rejected, so it turned to public bidding Shire is one of the world's most famous manufacturers of rare diseases Recently, she won the championship in a public awareness survey, and her business model is highly praised In 2014, he was the acquiree of over 50 billion US dollars in Alberta, but after the acquisition failed, shire turned to be an active "catcher" in the M & a market Baxalta, which was just separated from Baxter on July 1, is headquartered in Illinois, USA It is engaged in the development of biotherapy technology for rare blood diseases, cancer and immune system diseases It has been estimated that its annual revenue will reach 6 billion US dollars However, after the split, he quickly became the "prey" of the M & a market.